Vinblastinsulfat
Vinblastine Sulfate
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
143-67-9- Standard-SMILES
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O- InChIKey
KDQAABAKXDWYSZ-PNYVAJAMSA-N- Summenformel
- C46H58N4O9.H2O4S
- Durchschnittliche Molmasse
- 909,1 g/mol
- Monoisotopische Masse
- 908,38775898
Überblick
Vinblastine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
Namen und Bezeichner
- Bevorzugter Name
- Vinblastine Sulfate
- IUPAC
- methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid
- Lokaler Name
- Vinblastinsulfat
- Englischer Name
- Vinblastine sulfate
- Summenformel
- C46H60N4O13S
- Molmasse
- 909.06
Namen und Synonyme
Vinblastine sulfate143-67-9VelsarAlkaban-aqVinblastine sulphateVLB monosulfate29060-LEVincaleucoblastine sulfateVinblastini sulfasNSC-49842N00W22YO2BVincaleukoblastine, sulfate (1:1) (salt)
Weitere Namen anzeigen
VINBLASTINE SULFATE SALTVLBexalvelbanVINCALEUKOBLASTINEvelbensc49842
29060LE29060 LENSC 49842DTXSID601017133CHEBI:9984Vinblast,lederleSulfate, VinblastineRefChem:56475
Datenbank-Bezeichner
- CAS
143-67-9- PubChem CID
- 5388983
- DTXSID
DTXSID601017133- ChEMBL
Eigenschaften
Berechnete StruktureigenschaftenWird ergänzt
- Polarare Oberfläche (TPSA)
- 237 Ų
- H-Brücken-Donoren
- 5
- H-Brücken-Akzeptoren
- 16
- Frei drehbare Bindungen
- 10
- Schwere Atome
- 64
- Formalladung
- 0
- Komplexität
- 1.780
Experimentelle und physikochemische Eigenschaften
Solubilitygreater than or equal to 10 mg/mL at 76.1 °F (NTP, 1992)
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Antimitotic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Melting Point543 to 545 °F (NTP, 1992)
Physical DescriptionVinblastine sulfate appears as an anticancer drug. White to slightly yellow crystalline powder. (NTP, 1992)
Collision Cross Section278.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Physikochemische Eigenschaften
- Schmelzpunkt
- 267 °C · 267 °C (dec.)(lit.)
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- 2 O: · H2O: 10 mg/mL
- Aggregatzustand
- powder
- pka
- 7.4 · 7.4
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H302 (99%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 98 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory InformationHazard Traits - Developmental Toxicity
Other Safety InformationIMAP assessments - Vincaleukoblastine, sulfate (1:1) (salt): Environment tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however it is probably combustible. (NTP, 1992)
Health Hazards
SYMPTOMS: Symptoms of exposure to this chemical include temporary mental depression, paresthesias, loss of deep-tendon reflexes, headache, convulsions, psychoses; dysfunction of the autonomic nervous system, with marked constipation, paralytic ileus, urinary retention, bilateral pain and tenderness of the parotid glands associated with dryness of the mouth, sinus tachycardia; nausea, vomiting, anorexia, diarrhea; loss of hair, vesicular mucositis of the mouth, and dermatitis. (NTP, 1992)
Reactive GroupAlcohols and Polyols
Reactivity ProfileThis compound is sensitive to light, hydrolysis, oxidation, and heat. It is very hygroscopic. (NTP, 1992).
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
VINBLASTINE SULFATE
Vinca Alkaloid [EPC]; Vinca Alkaloids [CS]
MeSH Pharmacological Classification
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
Anwendungen
BeschreibungVinblastine sulfate is the salt of an alkaloid extracted from Vinca rosea Linn., a common flowering herb known as the periwinkle (more properly known as Catharanthus roseus G. Don). Previously, the generic name was vincaleukoblastine, abbreviated VLB. It is a stathmokinetic oncolytic agent. When treated in vitro with this preparation, growing cells are arrested in metaphase. Chemical and physical evidence indicate that vinblastine sulfate is a dimeric alkaloid containing both indole and dihydroindole moieties.
VerwendenAnticancer agent; microtubule disrupter; Induces apoptosis.Vinblastine sulfate is therapeutically used as an antineoplastic. It is also used in the treatment of Hodgkin disease, choriocarcinoma, acute and chronic leukemias.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
6
Notizen zur Verbindung
Wird geladen…